Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 836845 plus enzalutamide versus enzalutamide in metastatic castration-resistant prostate cancer after docetaxel and abiraterone
NL-OMON43930Phase 2Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2016
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in castration-resistant prostate cancer (CRPC) comparing Enzalutamide with BI 836845 + enzalutamide (2 arms). Primary endpoint: Radiological progression-free survival. Started Feb 2016; status: active, not recruiting.
02
Drugs
xentuzumabenzalutamide
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NL-OMON43930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43930.